Siglion is founded on seminal discoveries Veiseh made as a post-doctoral fellow in the laboratories of Bob Langer and Dan Anderson at Massachusetts Institute of Technology and Harvard Medical School.
“The project was aimed at developing biomaterials with improved biocompatibility that could enable cell transplantation for the treatment of type 1 diabetes,” says Veiseh of his work. “We were able to make significant strides towards this goal.”
After co-founding Siglion, Veiseh was offered a faculty position in the department of Bioengineering at Rice University. He postponed his start date so that he could join Sigilon full time to help build the company
“The most rewarding aspect of my job has been working with our world-class team at Sigilon,” says Veiseh of his job. “Everyone in the organization is motivated and passionate about making an impact. We work hard but we have a lot of fun doing what we do.”
In his free time, Veiseh enjoys spending time with his wife and two children.
Send this to a friend